Wells Fargo & Company Kempharm, Inc Transaction History

Wells Fargo & Company

$410 Billion
Q1 2024

A detailed history of Wells Fargo & Company transactions in Kempharm, Inc stock. As of the latest transaction made, Wells Fargo & Company holds 23,908 shares of KMPH stock, worth $118,105. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,908

Previous 23,759 0.63%

Holding current value

$118,105

Previous $117,000 0.85%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	N/A	149 Added 0.63%	23,908 $118,000
Q4 2023 Feb 09, 2024	BUY	N/A	2,788 Added 13.29%	23,759 $117,000
Q3 2023 Nov 13, 2023	BUY	N/A	2,921 Added 16.18%	20,971 $103,000
Q2 2023 Aug 15, 2023	BUY	$4.94 - $6.29 $64,086 - $81,600	12,973 Added 255.52%	18,050 $89,000
Q1 2023 May 12, 2023	BUY	$4.13 - $6.27 $12 - $18	3 Added 0.06%	5,077 $27,000

Q4 2022 Feb 13, 2023	SELL	$4.12 - $5.62 $313 - $427	-76 Reduced 1.48%	5,074 $23,000
Q3 2022 Nov 14, 2022	SELL	$4.5 - $6.85 $4,666 - $7,103	-1,037 Reduced 16.76%	5,150 $32,000
Q2 2022 Aug 12, 2022	SELL	$4.02 - $5.21 $11,814 - $15,312	-2,939 Reduced 32.2%	6,187 $27,000
Q1 2022 May 16, 2022	SELL	$5.0 - $9.26 $52,030 - $96,359	-10,406 Reduced 53.28%	9,126 $47,000
Q4 2021 Feb 14, 2022	SELL	$7.6 - $10.26 $150,016 - $202,522	-19,739 Reduced 50.26%	19,532 $171,000
Q3 2021 Nov 15, 2021	BUY	$8.72 - $13.31 $292,573 - $446,577	33,552 Added 586.68%	39,271 $366,000
Q2 2021 Aug 16, 2021	BUY	$8.52 - $15.47 $20,396 - $37,035	2,394 Added 72.0%	5,719 $73,000
Q1 2021 May 13, 2021	BUY	$5.6 - $13.47 $18,620 - $44,787	3,325 New	3,325 $30,000

Others Institutions Holding KMPH

# of Institutions

Shares Held

13.8M

Call Options Held

68.1K

Put Options Held

42K

View Full List

About KEMPHARM, INC

Ticker KMPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,493,600
Market Cap $170M
Description
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...

More about KMPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Kempharm, Inc Transaction History